We provide evidence that risk aversion leads pharmaceutical firms to underinvest in radical andnovel innovation. We do so by introducing a new measure of novelty: a drug candidate is novelif it is molecularly distinct from prior candidates. Using our measure, we show that firms face arisk-reward...

In recent years, there have been a number of high profile scandals on college campuses, ranging from cheating to hazing to rape. With so much information regarding a college's academic and non-academic attributes available to students, how do these scandals affect their applications? To...